COLORECTAL CANCER THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In May 2023, Biocartis Group NV, a molecular diagnostics company, and HiloProbe, a biotechnology company that focuses on personalizing colorectal cancer diagnostics, announced a collaboration that will initially focus on the commercialization of ColoNode, a CE-marked IVD gene expression signature test that can help detect nodal metastasis in patients with colorectal cancer
• In March 2023, Alembic Pharmaceuticals, an India-based pharmaceutical company, received final approval from the U.S. FDA for Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) pharmacy bulk vial. The injection is used for the treatment of patients with adenocarcinoma of colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma, and pancreatic adenocarcinoma

In February 2023, MEI Pharma, Inc., a clinical-stage pharmaceutical company, and Infinity Pharmaceuticals, Inc., a clinical-stage biotechnology company, announced a definitive merger agreement for an all-stock transaction forming a company combining MEI and Infinity's expertise and resources to advance a robust pipeline of three clinical-stage oncology drug candidates. ME-344, a novel tumor selective mitochondrial inhibitor targeting the OXPHOS pathway, is one of the drug candidates being tested in patients with relapsed colorectal cancer in combination with bevacizumab (AVASTIN).